Resveratrol suppresses oxidised low-density lipoprotein-induced macrophage apoptosis through inhibition of intracellular reactive oxygen species generation, lox-1, and the p38 MAPK pathway

Cellular Physiology and Biochemistry

Volumn 34, Issue 2, 2014, Pages 603-616

  Guo, Rong ^a   Su, Yang ^a   Liu, Baoxin ^a   Li, Shuang ^a   Zhou, Shunping ^a   Xu, Yawei ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Atherosclerosis; Macrophage apoptosis; MAPK; ox LDL; Resveratrol

Indexed keywords

CASPASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PROTEIN BAX; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; RESVERATROL; LOW DENSITY LIPOPROTEIN; OLR1 PROTEIN, MOUSE; STILBENE DERIVATIVE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; MACROPHAGE; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION; ANIMAL; CELL LINE; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; MOUSE; OXIDATION REDUCTION REACTION; PHYSIOLOGY; ANTIOXIDANT ACTIVITY; CELL MEMBRANE DEPOLARIZATION; CELL PROTECTION; CYTOTOXICITY; ENZYME ACTIVATION; FOAM CELL; MITOCHONDRIAL MEMBRANE;

ANIMALS; APOPTOSIS; CELL LINE; LIPOPROTEINS, LDL; MACROPHAGES; MICE; OXIDATION-REDUCTION; P38 MITOGEN-ACTIVATED PROTEIN KINASES; REACTIVE OXYGEN SPECIES; SCAVENGER RECEPTORS, CLASS E; STILBENES;

RICE STRIPE VIRUS;

EID: 84907303895     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000363026     Document Type: Article

References (52)

1. Hiesinger W, Cohen JE, Atluri P: Therapeutic potential of Rb phosphorylation in atherosclerosis. Cell Cycle DOI: 10.4161/cc.27551.
2. Ghattas A, Griffiths HR, Devitt A, Lip GY, Shantsila E: Monocytes in coronary artery disease and atherosclerosis: where are we now? J Am Coll Cardiol 2013;62:1541-1551.
3. Guo R, Li Y, Xu Y, Tang K, Li W: Significance of fragmented QRS complexes for identifying culprit lesions in patients with non-ST-elevation myocardial infarction: a single-center, retrospective analysis of 183 cases. BMC Cardiovasc Disord 2012;12:44.
4. Moore KJ, Sheedy FJ, Fisher EA: Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol 2013;13:709-721.
5. Maiolino G, Rossitto G, Caielli P, Bisogni V, Rossi GP, Calo LA: The Role of Oxidized Low-Density Lipoproteins in Atherosclerosis: The Myths and the Facts. Mediators Inflamm DOI: 10.1155/2013/714653.
6. Imanishi T, Akasaka T: Novel strategies to target inflammatory processes in atherosclerosis. Curr Pharm Des 2013;19:1616-1625.
7. Zeng HT, Fu YC, Yu W, Lin JM, Zhou L, Liu L, Wang W: SIRT1 prevents atherosclerosis via liver-X-receptor and NF-icB signaling in a U937 cell model. Mol Med Rep 2013;8:23-28.
8. Winnik S, Stein S, Matter CM: SIRT1 - an anti-inflammatory pathway at the crossroads between metabolic disease and atherosclerosis. Curr Vasc Pharmacol 2012;10:693-696.
9. Ota H, Eto M, Ogawa S, Iijima K, Akishita M, Ouchi Y: SIRT1/eNOS axis as a potential target against vascular senescence, dysfunction and atherosclerosis. J Atheroscler Thromb 2010;17:431-435.
10. Stein S, Lohmann C, Schafer N, Hofmann J, Rohrer L, Besler C, Rothgiesser KM, Becher B, Hottiger MO, Boren J, McBurney MW, Landmesser U, Luscher TF, Matter CM: SIRT1 decreases Lox-1-mediated foam cell formation in atherogenesis. Eur Heart J 2010;31:2301-2309.
11. Voloshyna I, Hussaini SM, Reiss AB: Resveratrol in cholesterol metabolism and atherosclerosis. J Med Food 2012;15:763-773.
12. Li H, Xia N, Forstermann U: Cardiovascular effects and molecular targets of resveratrol. Nitric Oxide 2012;26:102-110.
13. Fuhrman B, Partoush A, Volkova N, Aviram M: Ox-LDL induces monocyte-to-macrophage differentiation in vivo: Possible role for the macrophage colony stimulating factor receptor (M-CSF-R). Atherosclerosis 2008;196:598-607.
14. Janero DR: Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radic Biol Med 1990;9:515-540.
15. Liu B, Zhang B, Guo R, Li S, Xu Y: Enhancement in efferocytosis of oxidized low-density lipoprotein-induced apoptotic RAW264.7 cells through Sirt1-mediated autophagy. Int J Mol Med 2014;33:523-533.
16. Williams KJ, Tabas I: The response-to-retention hypothesis of atherogenesis reinforced. Curr Opin Lipidol 1998;9:471-474.
17. Tabas I, Williams KJ, Boren J: Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007;116:1832-1844.
18. Gustafsson M, Boren J: Mechanism of lipoprotein retention by the extracellular matrix. Curr Opin Lipidol 2004;15:505-514.
19. Goldstein JL, Ho YK, Basu SK, Brown MS: Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci U S A 1979;76:333-337.
20. Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL, Steinberg D: Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci U S A 1984;81:3883-3887.
21. Kruth HS: Receptor-independent fluid-phase pinocytosis mechanisms for induction of foam cell formation with native low-density lipoprotein particles. Curr Opin Lipidol 2011;22:386-393.
22. Andres V, Pello OM, Silvestre-Roig C: Macrophage proliferation and apoptosis in atherosclerosis. Curr Opin Lipidol 2012;23:429-438.
23. Fiori JL, Shin YK, Kim W, Krzysik-Walker SM, Gonzalez-Mariscal I, Carlson OD, Sanghvi M, Moaddel R, Farhang K, Gadkaree SK, Doyle ME, Pearson KJ, Mattison JA, de Cabo R, Egan JM: Resveratrol prevents fj-cell dedifferentiation in nonhuman primates given a high-fat/high-sugar diet. Diabetes 2013;62:3500-3513.
24. Bruckbauer A, Zemel MB: Synergistic effects of metformin, resveratrol, and hydroxymethylbutyrate on insulin sensitivity. Diabetes Metab Syndr Obes 2013;6:93-102.
25. Soufi FG, Vardyani M, Sheervalilou R, Mohammadi M, Somi MH: Long-term treatment with resveratrol attenuates oxidative stress pro-inflammatory mediators and apoptosis in streptozotocin-nicotinamide-induced diabetic rats. Gen Physiol Biophys 2012;31:431-438.
26. Das DK, Sato M, Ray PS, Maulik G, Engelman RM, Bertelli AA, Bertelli A: Cardioprotection of red wine: role of polyphenolic antioxidants. Drugs Exp Clin Res 1999;25:115-120.
27. Baur JA, Sinclair DA: Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006;5:493-506.
28. Bravo-San Pedro JM, Senovilla L: Immunostimulatory activity of lifespan-extending agents. Aging (Albany NY) 2013;5:793-801.
29. Singh CK, George J, Ahmad N: Resveratrol-based combinatorial strategies for cancer management. Ann N Y Acad Sci 2013;1290:113-121.
30. Thushara RM, Hemshekhar M, Santhosh MS, Devaraja S, Kemparaju K, Girish KS: Differential action of phytochemicals on platelet apoptosis: a biological overview. Curr Med Chem 2013;20:1018-1027.
31. Stein S, Matter CM: Protective roles of SIRT1 in atherosclerosis. Cell Cycle 2011;10:640-647.
32. Barger JL, Kayo T, Vann JM, Arias EB, Wang J, Hacker TA, Wang Y, Raederstorff D, Morrow JD, Leeuwenburgh C, Allison DB, Saupe KW, Cartee GD, Weindruch R, Prolla TA: A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS One 2008;3:e2264.
33. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu W, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R, Sinclair DA: Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006;444:337-342.
34. Palsamy P, Subramanian S: Resveratrol, a natural phytoalexin, normalizes hyperglycemia in streptozotocin-nicotinamide induced experimental diabetic rats. Biomed Pharmacother 2008;62:598-605.
35. Sinha K, Das J, Pal PB, Sil PC: Oxidative stress: the mitochondria-dependent and mitochondria-independent pathways of apoptosis. Arch Toxicol 2013;87:1157-1180.
36. Ueda S, Masutani H, Nakamura H, Tanaka T, Ueno M, Yodoi J: Redox control of cell death. Antioxid Redox Signal 2002;4:405-414.
37. Borras C, Gomez-Cabrera MC, Vina J: The dual role of p53: DNA protection and antioxidant. Free Radic Res 2011;45:643-652.
38. Shiizaki S, Naguro I, Ichijo H: Activation mechanisms of ASK1 in response to various stresses and its significance in intracellular signaling. Adv Biol Regul 2013;53:135-144.
39. Lu TH, Tseng TJ, Su CC, Tang FC, Yen CC, Liu YY, Yang CY, Wu CC, Chen KL, Hung DZ, Chen YW: Arsenic induces reactive oxygen species-caused neuronal cell apoptosis through JNK/ERK-mediated mitochondria-dependent and GRP 78/CHOP-regulated pathways. Toxicol Lett 2014;224:130-140.
40. Hsieh CJ, Kuo PL, Hsu YC, Huang YF, Tsai EM, Hsu YL: Arctigenin, a dietary phytoestrogen, induces apoptosis of estrogen receptor-negative breast cancer cells through the ROS/p38 MAPK pathway and epigenetic regulation. Free Radic Biol Med 2013;67C:159-170.
41. Yoshimoto R, Fujita Y, Kakino A, Iwamoto S, Takaya T, Sawamura T: The discovery of LOX-1, its ligands and clinical significance. Cardiovasc Drugs Ther 2011;25:379-391.
42. Xu S, Ogura S, Chen J, Little PJ, Moss J, Liu P: LOX-1 in atherosclerosis: biological functions and pharmacological modifiers. Cell Mol Life Sci 2013;70:2859-2872.
43. Zhang K, Meng X, Kong J, Liu FF, Yang JM, Gao F, Zhang Y, Zhang C: Simvastatin increases Prolyl-4-Hydroxylase a1 expression in atherosclerotic plaque and ox-LDL-stimulated human aortic smooth muscle cells via p38 MAPK and ERK1/2 signaling. J Mol Cell Cardiol 2013;65:43-50.
44. del Barco Barrantes I, Nebreda AR: Roles of p38 MAPKs in invasion and metastasis. Biochem Soc Trans 2012;40:79-84.
45. Cuadrado A, Nebreda AR: Mechanisms and functions of p38 MAPK signalling. Biochem J 2010;429:403-417.
46. Wang WL, Meng ZX, Zhou SJ, Li CJ, Chen R, Lv L, Ma ZJ, Yu DM, Yu P: Reduced beta2-glycoprotein I protects macrophages from ox-LDL-induced foam cell formation and cell apoptosis. Lipids Health Dis 2013;12:174.
47. Yin Y, Liu W, Ji G, Dai Y: The essential role of p38 MAPK in mediating the interplay of oxLDL and IL-10 in regulating endothelial cell apoptosis. Eur J Cell Biol 2013;92:150-159.
48. Yu JY, Zheng ZH, Son YO, Shi X, Jang YO, Lee JC: Mycotoxin zearalenone induces AIF- and ROS-mediated cell death through p53- and MAPK-dependent signaling pathways in RAW264.7 macrophages. Toxicol In Vitro 2011;25:1654-1663.
49. Deby-Dupont G, Mouithys-Mickalad A, Serteyn D, Lamy M, Deby C: Resveratrol and curcumin reduce the respiratory burst of Chlamydia-primed THP-1 cells. Biochem Biophys Res Commun 2005;333:21-27.
50. Voloshyna I, Hai O, Littlefield MJ, Carsons S, Reiss AB: Resveratrol mediates anti-atherogenic effects on cholesterol flux in human macrophages and endothelium via PPARy and adenosine. Eur J Pharmacol 2013;698:299-309.
51. Park JW, Choi YJ, Suh SI, Baek WK, Suh MH, Jin IN, Min DS, Woo JH, Chang JS, Passaniti A, Lee YH, Kwon TK: Bcl-2 overexpression attenuates resveratrol-induced apoptosis in U937 cells by inhibition of caspase-3 activity. Carcinogenesis 2001;22:1633-1639.
52. Tsan MF, White JE, Maheshwari JG, Bremner TA, Sacco J: Resveratrol induces Fas signalling-independent apoptosis in THP-1 human monocytic leukaemia cells. Br J Haematol 2000;109:405-412.